143 related articles for article (PubMed ID: 11004663)
1. Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation.
Preuss U; Kreutzfeld R; Scheidtmann KH
Int J Cancer; 2000 Oct; 88(2):162-71. PubMed ID: 11004663
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes.
Lohrum M; Scheidtmann KH
Oncogene; 1996 Dec; 13(12):2527-39. PubMed ID: 9000127
[TBL] [Abstract][Full Text] [Related]
3. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
4. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells.
Deb S; Jackson CT; Subler MA; Martin DW
J Virol; 1992 Oct; 66(10):6164-70. PubMed ID: 1356162
[TBL] [Abstract][Full Text] [Related]
6. Increased oncogenicity of subclones of SV40 large T-induced neuroectodermal tumor cell lines after loss of large T expression and concomitant mutation in p53.
Salewski H; Bayer TA; Eidhoff U; Preuss U; Weggen S; Scheidtmann KH
Cancer Res; 1999 Apr; 59(8):1980-6. PubMed ID: 10213510
[TBL] [Abstract][Full Text] [Related]
7. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
8. A significant decrease of the transcriptional activity of p53 mutants deriving from human functional adrenal tumors.
Lin SR; Yang YC; Jung JH; Tsai JH
DNA Cell Biol; 1996 Oct; 15(10):793-803. PubMed ID: 8892752
[TBL] [Abstract][Full Text] [Related]
9. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
10. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
[TBL] [Abstract][Full Text] [Related]
11. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.
Ludwig RL; Bates S; Vousden KH
Mol Cell Biol; 1996 Sep; 16(9):4952-60. PubMed ID: 8756654
[TBL] [Abstract][Full Text] [Related]
12. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation.
Hall SR; Campbell LE; Meek DW
Nucleic Acids Res; 1996 Mar; 24(6):1119-26. PubMed ID: 8604347
[TBL] [Abstract][Full Text] [Related]
14. WT1-p53 interactions in insulin-like growth factor-I receptor gene regulation.
Idelman G; Glaser T; Roberts CT; Werner H
J Biol Chem; 2003 Jan; 278(5):3474-82. PubMed ID: 12444079
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
17. A point mutation of human p53, which was not detected as a mutation by a yeast functional assay, led to apoptosis but not p21Waf1/Cip1/Sdi1 expression in response to ionizing radiation in a human osteosarcoma cell line, Saos-2.
Okaichi K; Wang LH; Sasaki J; Saya H; Tada M; Okumura Y
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):975-80. PubMed ID: 10571205
[TBL] [Abstract][Full Text] [Related]
18. Investigations on a clinically and functionally unusual and novel germline p53 mutation.
Rutherford J; Chu CE; Duddy PM; Charlton RS; Chumas P; Taylor GR; Lu X; Barnes DM; Camplejohn RS
Br J Cancer; 2002 May; 86(10):1592-6. PubMed ID: 12085209
[TBL] [Abstract][Full Text] [Related]
19. Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization.
Jõers A; Kristjuhan A; Kadaja L; Maimets T
Oncogene; 1998 Nov; 17(18):2351-8. PubMed ID: 9811466
[TBL] [Abstract][Full Text] [Related]
20. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene.
Chen J; Lin J; Levine AJ
Mol Med; 1995 Jan; 1(2):142-52. PubMed ID: 8529093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
